Ascendia

  MARKET NEWS

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
EMA Confirms Acceptance of Marketing Authorization Application for a Proposed Biosimilar to Simponi
Can-Fite Anti-Obesity Drug Received Patent Allowance in Australia
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
SGS Announces Expansion of Biopharmaceutical Testing Capabilities
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease & Neuroscience Pipeline
Quotient Sciences & Medicines for Malaria Venture Announce Dosing of First-Ever Long-Acting Injectable for Malaria Prevention to Study Volunteers
Intensity Therapeutics & The Swiss Group for Clinical Cancer Research SAKK Announce First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial
Curevo Presents Positive Shingles Vaccine Outcomes Data
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

  EXPERT CONTENT & RESOURCES

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

CPHI Annual Report 2024: Drug Delivery Trends & Insights From a Device Perspective

Significant growth in the drug delivery sector is predicted for many areas, with headliners including cell and gene therapies and the GLP-1 blockbusters. Small molecule-based formulations still dominate innovator pipelines, but advanced biologics are also….

  FEATURED EDITORIAL

  COMPANY PROFILE

AustinPx was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That’s where we come in. Our client-centric approach is designed to simplify the complexity of outsourcing and our team of formulation, analytical, and manufacturing experts work with you to overcome challenges and identify opportunities to do more, faster. As the inventors of KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) technology for poorly soluble APIs, with its smaller footprint, broader design space, and greener processing solutions, we aim to disrupt the ASD industry. Click here for more.

  WHITEPAPERS & WEBINARS

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Private: WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay

Whether you’re involved in research, development, or quality control, this webinar will equip you with the knowledge and tools you need to enhance your analytical processes and ensure success in your LNP projects.

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 13 – Parenteral Contract Manufacturing
November 20 – Particle Design Technology